Atlas Molecular Pharma - About the company
Atlas Molecular Pharma is a series A company based in Derio (Spain), founded in 2015. It operates as a Develops proprietary drug discovery platform. Atlas Molecular Pharma has raised $3.4M in funding. The company has 1949 active competitors, including 452 funded and 335 that have exited. Its top competitors include companies like Synthego, Antheia and Transcenta.
Company Details
Atlas Molecular Pharma engages in developing drug discovery platform called CHASSYS. The technology is an integrated platform to develop new chemical entities and repurposed drugs. It is currently working on Congenital Erythropoietic Porphyria wherein the autosomal recessive deficiency in the uroporphyrinogen III synthase (UROIIIS) enzyme causes build up of porphyrins in high concentration. Additionally, the company is also working on Prion Disease: and Tyrosianemia along with other diseases.
- Website
- atlasmolecularpharma.com
- Social
- Email ID
- *****@atlasmolecularpharma.com
Key Metrics
Founded Year
2015
Location
Derio, Spain
Stage
Series A
Total Funding
$3.4M in 3 rounds
Latest Funding Round
Ranked
121st among 1949 active competitors
Employee Count
4 as on Jul 01, 2024
Sign up to download Atlas Molecular Pharma's company profile
Atlas Molecular Pharma's funding and investors
Atlas Molecular Pharma has raised a total funding of $3.4M over 3 rounds. Its first funding round was on 2016. Its latest funding round was a Series A round on Jan 09, 2022 for $*****. 5 investors participated in its latest round. Atlas Molecular Pharma has 6 institutional investors.
Here is the list of recent funding rounds of Atlas Molecular Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 09, 2022 | 2890432 | Series A | 8506775 | 7028175 | 6815073 | 7537952 |
Mar 01, 2021 | 3841454 | Grant (prize money) | 3496784 | 6815417 | 4897567 | |
2016 | 7720 | Seed | 7280 | 3602 | 6406 |
Access funding benchmarks and valuations. Sign up today!View details of Atlas Molecular Pharma's funding rounds and investors
Atlas Molecular Pharma's founders and board of directors
Founder? Claim ProfileAtlas Molecular Pharma's employee count trend
Atlas Molecular Pharma has 4 employees as of Jul 24. Here is Atlas Molecular Pharma's employee count trend over the years:
Uncover Atlas Molecular Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Atlas Molecular Pharma's Competitors and alternates
Top competitors of Atlas Molecular Pharma include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Atlas Molecular Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Synthego 2012, Redwood City (United States), Acquired | Developer of CRISPR-engineered cell and gene therapies | $460M | 71/100 | |
2nd | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
3rd | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
4th | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
5th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
6th | Life Biosciences 2017, Boston (United States), Series D | Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases | $261M | 64/100 | |
7th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
8th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
9th | Dewpoint Therapeutics 2018, Boston (United States), Series D | Developer of small molecule based therapeutics | $346M | 62/100 | |
10th | Developer of oral non-viral gene therapy platform | $54M | 62/100 | ||
121st | Atlas Molecular Pharma 2015, Derio (Spain), Series A | Develops proprietary drug discovery platform | $3.4M | 48/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Atlas Molecular Pharma's competitors? Click here to see the top ones
Atlas Molecular Pharma's Investments and acquisitions
Atlas Molecular Pharma has made no investments or acquisitions yet.
News related to Atlas Molecular Pharma
Media has covered Atlas Molecular Pharma for a total of 2 events in the last 1 year.
•
Innvierte allocates 355 million euros to new co-investments and investment vehiclesEl Referente•Jan 30, 2026•Xoople, Alcyon Photonics, Orikine Bio, Atlas Molecular Pharma and 3 others
•
Atlas Molecular Pharma closes €3M round led by Inveready to advance its clinical program in rare diseasesWebcapitalriesgo•Jan 15, 2026•Spri, Atlas Molecular Pharma, CDTI, Kereon Partners and 2 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Atlas Molecular Pharma
Explore our recently published companies
- Infyner - Unfunded company
- Advanced Magnet Lab - Melbourne based, 1995 founded, Early Stage company
- Pazar - Zagreb based, 2021 founded, Unfunded company
- Seemann Pm - Hamburg based, Unfunded company
- PeakSpan - Sydney based, 2004 founded, Unfunded company
- Templarket Business Templates Marketplace - Poland based, 2020 founded, Unfunded company
